Bioxcel Therapeutics Stock Today
| BTAI Stock | USD 2.05 0.32 18.50% |
PerformanceWeak
| Odds Of DistressVery High
|
BioXcel Therapeutics is trading at 2.05 as of the 26th of June 2025. This is a 18.50 percent increase since the beginning of the trading day. The stock's open price was 1.73. BioXcel Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 28th of March 2025 and ending today, the 26th of June 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of March 2018 | Category Healthcare | Classification Health Care |
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut. The company has 6.06 M outstanding shares of which 515.65 K shares are currently shorted by private and institutional investors with about 1.38 trading days to cover. More on BioXcel Therapeutics
Moving together with BioXcel Stock
Moving against BioXcel Stock
BioXcel Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Vimal Mehta | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBioXcel Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioXcel Therapeutics' financial leverage. It provides some insight into what part of BioXcel Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioXcel Therapeutics (BTAI) is traded on NASDAQ Exchange in USA. It is located in 555 Long Wharf Drive, New Haven, CT, United States, 06511 and employs 37 people. BioXcel Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.41 M. BioXcel Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.06 M outstanding shares of which 515.65 K shares are currently shorted by private and institutional investors with about 1.38 trading days to cover.
BioXcel Therapeutics currently holds about 233.45 M in cash with (72.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check BioXcel Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of BioXcel Therapeutics is $12.41 Million. BioXcel Therapeutics shows 8.65 percent of its outstanding shares held by insiders and 11.02 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check BioXcel Ownership Details
BioXcel Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Group One Trading, Lp | 2025-03-31 | 1.3 K | |
| Sbi Securities Co Ltd | 2025-03-31 | 851 | |
| Federated Hermes Inc | 2025-03-31 | 237 | |
| Allsquare Wealth Management Llc | 2025-03-31 | 175 | |
| Washington Trust Advisors, Inc. | 2025-03-31 | 160 | |
| Tower Research Capital Llc | 2025-03-31 | 152 | |
| Jpmorgan Chase & Co | 2025-03-31 | 116 | |
| Parkside Financial Bank & Trust | 2025-03-31 | 112 | |
| Zurcher Kantonalbank | 2025-03-31 | 103 | |
| Murchinson Ltd. | 2025-03-31 | 136.1 K | |
| Goldman Sachs Group Inc | 2025-03-31 | 24.8 K |
BioXcel Therapeutics Historical Income Statement
BioXcel Stock Against Markets
BioXcel Therapeutics Corporate Management
| Javier JD | Chief VP | Profile | |
| Frank Yocca | Chief Scientific Officer | Profile | |
| Mary Coleman | VP Relations | Profile | |
| Javier Rodriguez | Chief VP | Profile | |
| Cedric Burg | VP Management | Profile | |
| Robert Scala | Vice Planning | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.12) | Revenue Per Share | Quarterly Revenue Growth (0.71) | Return On Assets | Return On Equity |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.